Actualités

Tempus AI stock has fallen 22.4% year to date, yet the valuation checks paint a mixed picture rather than a clear bargain or clear overvaluation. This puts the recent share price weakness under scrutiny. Year to date, Tempus AI is down 22.4%, a move that raises the question of whether sentiment has swung too far relative to the company’s fundamentals. On the positive side, progress in deploying its prostate cancer AI tools in real clinical settings can support expectations for future...

The brokerage said the acquisition strengthens Tempus AI’s precision oncology business, though near-term financials are less compelling.

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t

By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with CTA313 in systemic lupus erythematosus is highly encouraging, with 100% of patients achieving an SRI-4 […]